Inflammatory Rheumatic Disorders and Bone

被引:103
作者
Bultink, Irene E. M. [1 ]
Vis, Marijn [2 ]
van der Horst-Bruinsma, Irene E. [1 ]
Lems, Willem F. [3 ,4 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, NL-1081 HV Amsterdam, Netherlands
[2] Erasmus MC, Dept Rheumatol, NL-3015 GE Rotterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, NL-1081 HV Amsterdam, Netherlands
[4] Reade, NL-1081 HV Amsterdam, Netherlands
关键词
Osteoporosis; Fractures; Rheumatoid arthritis; Systemic lupus erythematosus; SLE; Ankylosing spondylitis; Metabolic bone disease; Inflammation; Bone; SYSTEMIC-LUPUS-ERYTHEMATOSUS; VITAMIN-D DEFICIENCY; MINERAL DENSITY; VERTEBRAL FRACTURES; RISK-FACTORS; PREMENOPAUSAL WOMEN; FEMALE-PATIENTS; SERUM-LEVELS; SLE PATIENTS; PREVALENCE;
D O I
10.1007/s11926-012-0252-8
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Inflammatory joint diseases such as rheumatoid arthritis, as well as other rheumatic conditions, such as systemic lupus erythematosus (SLE) and ankylosing spondylitis, comprise a heterogeneous group of joint disorders that are all associated with extra-articular side effects, including bone loss and fractures. The concept of osteoimmunology is based on growing insights into the links between the immune system and bone. The pathogenesis of osteoporosis in these patients is multifactorial. We have, more or less as an example, described this extensively for patients with SLE. High disease activity (inflammation) and immobility are common factors that substantially increase fracture risk in these patients, on top of the background fracture risk based on, among other factors, age, body mass index, and gender. Although no fracture reduction has been shown in intervention studies in patients with inflammatory rheumatic diseases, we present treatment options that might be useful for clinicians who are treating these patients.
引用
收藏
页码:224 / 230
页数:7
相关论文
共 68 条
[1]
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α [J].
Allali, F ;
Breban, M ;
Porcher, R ;
Maillefert, JF ;
Dougados, M ;
Roux, C .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (04) :347-349
[2]
Prevalence and risk factors of osteoporosis in female SLE patients - extended report [J].
Almehed, K. ;
d'Elia, H. Forsbad ;
Kvisti, G. ;
Ohlsson, C. ;
Carlsten, H. .
RHEUMATOLOGY, 2007, 46 (07) :1185-1190
[3]
Amin S., 2011, J BONE MINER RES S1, V26
[4]
The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis [J].
Arends, S. ;
Spoorenberg, A. ;
Bruyn, G. A. W. ;
Houtman, P. M. ;
Leijsma, M. K. ;
Kallenberg, C. G. M. ;
Brouwer, E. ;
van der Veer, E. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (05) :1431-1439
[5]
Vitamin D deficiency in patients with active systemic lupus erythematosus [J].
Borba, V. Z. C. ;
Vieira, J. G. H. ;
Kasamatsu, T. ;
Radominski, S. C. ;
Sato, E. I. ;
Lazaretti-Castro, M. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (03) :427-433
[6]
Bone mineral density changes in women with systemic lupus erythematosus [J].
Boyanov, M ;
Robeva, R ;
Popivanov, P .
CLINICAL RHEUMATOLOGY, 2003, 22 (4-5) :318-323
[7]
Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus [J].
Bultink, IEM ;
Lems, WF ;
Kostense, PJ ;
Dijkmans, BAC ;
Voskuyl, AE .
ARTHRITIS AND RHEUMATISM, 2005, 52 (07) :2044-2050
[8]
Osteoporosis and fractures in systemic lupus erythematosus [J].
Bultink, Irene E. M. .
ARTHRITIS CARE & RESEARCH, 2012, 64 (01) :2-8
[9]
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis [J].
Cohen, Stanley B. ;
Dore, Robin K. ;
Lane, Nancy E. ;
Ory, Peter A. ;
Peterfy, Charles G. ;
Sharp, John T. ;
van der Heijde, Desiree ;
Zhou, Lifen ;
Tsuji, Wayne ;
Newmark, Richard .
ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1299-1309
[10]
COOPER C, 1994, J RHEUMATOL, V21, P1877